(Total Views: 86)
Posted On: 05/04/2021 12:14:29 PM
Post# of 23614
$NBIO Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note
Press Release | 05/04/2021
SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"
, a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce further strides toward the elimination of toxic debt and dilution risk with the preemptive settlement of its outstanding convertible note liability (the "Note" held by Harbor Gate Capital LLC ("Harbor Gate" . https://www.otcmarkets.com/stock/NBIO/news/Na...?id=301259
Press Release | 05/04/2021
SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"
, a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce further strides toward the elimination of toxic debt and dilution risk with the preemptive settlement of its outstanding convertible note liability (the "Note" held by Harbor Gate Capital LLC ("Harbor Gate" . https://www.otcmarkets.com/stock/NBIO/news/Na...?id=301259
(0)
(0)
